RxDoctor Payments Data

Michael McCracken, MD

Ophthalmic Plastic and Reconstructive Surgery · Parker, CONPI 1043291701

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 58.8% of the total.

$3,869in general payments, 2019–2025

Across 103 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Galderma Laboratories, L.p.$616
  • Merz North America, Inc.$343
  • Stryker$325
  • Amgen$158
  • Revance Therapeutics, Inc.$121
  • plus $32 from 1 others

What the payments were for

  • Food & beverage$3,869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,869 in reported general payments places this provider in the 80th percentile of 21 ophthalmic plastic and reconstructive surgery providers in Colorado.

See all ophthalmic plastic and reconstructive surgery providers in Colorado

Medicare billing

Part B allowed, 2024
$75,729
Medicare patients
113
Services billed
1,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base117$1,138
Celecoxib41$867
Minoxidil30$315
Doxycycline Hyclate11$140
Clonidine Hcl11$4

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Parker

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →